Outcomes of polymyalgia rheumatica in real-world practice : a longitudinal cohort study
© 2024 Mehran Rahimi et al., published by Sciendo..
Background: Polymyalgia rheumatica (PMR) is an inflammatory condition closely linked with giant cell arteritis, which is a large vessel vasculitis. To provide real-world evidence on PMR outcomes and their determinants, we conducted a longitudinal study focusing on symptom relief and acute phase reactant normalization. Methods: We followed patients with PMR who were registered in Tabriz University of Medical Sciences Vasculitis Registry (TUOMS-VR) until February 2023. We measured sustained remission (primary outcome) and secondary outcomes including glucocorticoids (GCs)-free remission, medication-free remission, relapse rate and disease-induced damage. Results: We identified eighty-one patients with PMR and followed them for a median time of 57 months. In a median duration of 3 weeks, 98.8% of patients achieved symptom control, with 86.4% achieving sustained remission in a median duration of 9 weeks. Sustained remission was more common in non-smokers and adherent to therapy patients. Relapse occurred in 22.1% of patients, primarily due to non-adherence. Medication-free remission was observed in 30.9% of patients, especially among females and those with an initial prednisolone dose > 15 mg/d. Damage occurred in 42.0% of patients. Conclusion: Although sustained remission in PMR is not an unattainable goal in daily practice and most patients are in remission at the last visit, two-thirds of patients require long-term treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Romanian journal of internal medicine = Revue roumaine de medecine interne - (2024) vom: 12. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rahimi, Mehran [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug Therapy |
|---|
| Anmerkungen: |
Date Revised 12.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2478/rjim-2024-0009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36960086X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36960086X | ||
| 003 | DE-627 | ||
| 005 | 20240312235006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2478/rjim-2024-0009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1325.xml |
| 035 | |a (DE-627)NLM36960086X | ||
| 035 | |a (NLM)38470357 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rahimi, Mehran |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of polymyalgia rheumatica in real-world practice |b a longitudinal cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Mehran Rahimi et al., published by Sciendo. | ||
| 520 | |a Background: Polymyalgia rheumatica (PMR) is an inflammatory condition closely linked with giant cell arteritis, which is a large vessel vasculitis. To provide real-world evidence on PMR outcomes and their determinants, we conducted a longitudinal study focusing on symptom relief and acute phase reactant normalization. Methods: We followed patients with PMR who were registered in Tabriz University of Medical Sciences Vasculitis Registry (TUOMS-VR) until February 2023. We measured sustained remission (primary outcome) and secondary outcomes including glucocorticoids (GCs)-free remission, medication-free remission, relapse rate and disease-induced damage. Results: We identified eighty-one patients with PMR and followed them for a median time of 57 months. In a median duration of 3 weeks, 98.8% of patients achieved symptom control, with 86.4% achieving sustained remission in a median duration of 9 weeks. Sustained remission was more common in non-smokers and adherent to therapy patients. Relapse occurred in 22.1% of patients, primarily due to non-adherence. Medication-free remission was observed in 30.9% of patients, especially among females and those with an initial prednisolone dose > 15 mg/d. Damage occurred in 42.0% of patients. Conclusion: Although sustained remission in PMR is not an unattainable goal in daily practice and most patients are in remission at the last visit, two-thirds of patients require long-term treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Drug Therapy | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Patient Outcome Assessment | |
| 650 | 4 | |a Polymyalgia Rheumatica | |
| 650 | 4 | |a Recurrence | |
| 650 | 4 | |a Remission Induction | |
| 650 | 4 | |a Treatment Outcome | |
| 700 | 1 | |a Esalatmanesh, Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Daneshvar, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Irvani, Seyed Sina Naghibi |e verfasserin |4 aut | |
| 700 | 1 | |a Badali, Ahmadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Khabbazi, Alireza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Romanian journal of internal medicine = Revue roumaine de medecine interne |d 1997 |g (2024) vom: 12. März |w (DE-627)NLM012803472 |x 2501-062X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2478/rjim-2024-0009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 03 | ||